In July 2023, interviewers met a woman living with HIV who was on 2nd-line antiretroviral therapy, but was having to use the pediatric formulation of lopinavir/ritonavir due to stock-outs of the adult formulation. This required her to take multiple pills and she became uncertain over the reliability of the medicines.
Action Taken: After a phone conversation with the Manipur State AIDS Control Society (MACS) about this case, MACS immediately procured the adult formulation of lopinavir/ritonavir from the market and provided it to the patient as an interim measure.